Conferences
ASCO GU 2024: Association Between SPECT/CT Total Tumor Volume and New Lesions in Early Cycles of 177Lu-PSMA-617 and PFS and OS in Men with mCRPC
January 28, 2024
ASCO GU 2024: Neoadjuvant Combined Chemotherapy and Immunotherapy for Upper Tract Urothelial Carcinoma: Preliminary Results From a Phase II Study
January 28, 2024
ASCO GU 2024: Association Between PET-Based TheraP Eligibility and 177Lu-PSMA-617 Outcomes in VISION-Eligible Patients with mCRPC
January 28, 2024
ASCO GU 2024: Implementation Outcomes of a Multidisciplinary Approach for Lu177-PSMA-617 Therapy
January 28, 2024
ASCO GU 2024: Evaluating Clinical Outcomes with Systemic Therapy Given After Progression on PSMA Radioligand Therapy in Patients with mCRPC
January 28, 2024
ASCO GU 2024: Neoadjuvant Nivolumab + Ipilimumab in Cisplatin-Ineligible Patients with Upper Tract Urothelial Cancer: Updated Results
January 28, 2024
ASCO GU 2024: Patient Reported Outcomes Among Patients with mCRPC by HRR Mutations Gene Clusters: Findings from the Phase 3 TALAPRO-2 Study Cohort 2
January 28, 2024
ASCO GU 2024: Patient Outcomes After Therapy with 177Lu-PSMA-617 for mCRPC: A Tertiary Center Experience
January 28, 2024